Intraductal papillary mucinous carcinoma of pancreas

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:424058C25.3
Who is this for?
Show terms as
16Active trials30Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Intraductal papillary mucinous carcinoma of the pancreas, often called IPMC or malignant IPMN (intraductal papillary mucinous neoplasm), is a type of pancreatic cancer that starts inside the ducts of the pancreas — the tubes that carry digestive juices. It begins as a slow-growing, mucus-producing growth called an IPMN, which over time can turn into cancer. The pancreas sits behind the stomach and plays two important roles: helping digest food and controlling blood sugar. When cancer develops in its ducts, it can block the flow of digestive enzymes and affect how the whole organ works. People with IPMC may notice symptoms like belly pain, unexplained weight loss, yellowing of the skin or eyes (jaundice), or new-onset diabetes. Because these symptoms can be vague and easy to overlook, the cancer is sometimes found late. Imaging tests like MRI or CT scans, along with endoscopic procedures, are key to finding and monitoring these tumors. Treatment depends on how far the cancer has spread. Surgery to remove part or all of the pancreas is the main option when the cancer is caught early and has not spread. Chemotherapy and radiation may also be used. Compared to other types of pancreatic cancer, IPMC that is caught before it spreads widely tends to have a better outlook, making early detection very important.

Also known as:

Key symptoms:

Dull or aching pain in the upper belly or backUnexplained weight lossYellowing of the skin or whites of the eyes (jaundice)Pale or greasy stoolsDark urineNausea or vomitingLoss of appetiteNew or worsening diabetesFeeling full quickly when eatingOily or floating stools due to poor fat digestionFatigue and general weaknessItchy skin (related to jaundice)

Inheritance

Multifactorial

Caused by a mix of several genes and environmental factors

Age of Onset

Adult

Begins in adulthood (age 18 or older)

Orphanet ↗NORD ↗

FDA & Trial Timeline

10 events
Sep 2025Intent of Surgery for IPMN

NYU Langone Health

TrialRECRUITING
Aug 2025Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer

Changhai Hospital

TrialRECRUITING
Jul 2025Surveillance Discontinuation in 5 Year Stable Trivial Branch Duct Intraductal Papillary Mucinous Neoplasms

Azienda Ospedaliera di Padova

TrialNOT YET RECRUITING
May 2025Impact of GLP-1 Receptor Agonists on Patients With IPMN

Hôpital Fribourgeois

TrialNOT YET RECRUITING
May 2025Feasibility Trial of EUS-PCA in IPMN Pancreatic Cysts

University of Auckland, New Zealand — NA

TrialNOT YET RECRUITING
May 2025Identification of New Theranostic Biomarkers of Pancreatic Tumor Progression

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

TrialRECRUITING
Feb 2025Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center

H. Lee Moffitt Cancer Center and Research Institute — NA

TrialACTIVE NOT RECRUITING
Jan 2025Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) Consortium

IRCCS San Raffaele

TrialRECRUITING
Oct 2024The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)

Adenocyte, LLC

TrialENROLLING BY INVITATION
Aug 2024AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort

Changhai Hospital

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Intraductal papillary mucinous carcinoma of pancreas.

16 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

16 recruitingView all trials with filters →
Phase 22 trials
The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)
Phase 2
Active
PI: Peter Allen, MD (Duke University) · Sites: Baltimore, Maryland; Boston, Massachusetts +2 more · Age: 2185 yrs
Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)
Phase 2
Active
PI: Mokenge P Malafa, MD, FACS (Moffitt Cancer Center) · Sites: Tampa, Florida; Omaha, Nebraska · Age: 1899 yrs
N/A1 trial
Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center
N/A
Active
PI: Jennifer Permuth, PhD (Moffitt Cancer Center) · Sites: Tampa, Florida · Age: 1899 yrs
Other13 trials
Intra-operative Pancreatoscopy in Patients With IPMN
Active
PI: Marco Del Chiaro, MD (University of Colorado, Denver) · Sites: Denver, Colorado; Indianapolis, Indiana +6 more · Age: 1899 yrs
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
Actively Recruiting
· Sites: Shanghai, Shanghai Municipality; Shanghai, Shanghai Municipality +3 more · Age: 5099 yrs
Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
Actively Recruiting
PI: Tingbo Liang, PhD (Zhejiang University) · Sites: Hangzhou, Zhejiang · Age: 090 yrs
Pancreatic Cancer Initial Detection Via Liquid Biopsy
Enrolling by Invitation
· Sites: Stockholm · Age: 1899 yrs
Intraductal Papillary Mucinous Neoplasm (IPMN) Database - A Tool to Predict Pancreatic Cancer
Actively Recruiting
PI: Adrian Fox (St Vincent's Hospital Melbourne) · Sites: Fitzroy, Victoria · Age: 1890 yrs
The LINFU® U.S. Registry in Patients With IPMN (Intraductal Papillary Mucinous Neoplasm of the Pancreas)
Enrolling by Invitation
PI: Gregory Haber, MD FRCP (Manhattan Endoscopy Center) · Sites: New York, New York · Age: 1890 yrs
Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) Consortium
Actively Recruiting
· Sites: Milan, MI · Age: 1899 yrs
Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
Actively Recruiting
PI: Jennifer Permuth, PhD (Moffitt Cancer Center) · Sites: Lakewood Rch, Florida; Miami, Florida +1 more · Age: 1899 yrs
Endocrine, Metabolic, Inflammatory Biomarkers to Identify Highgrade Dysplasia/invasive Carcinoma in Patients with IPMN of the Pancreas
Actively Recruiting
· Sites: Milan, Italy · Age: 1899 yrs
AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort
Actively Recruiting
PI: Jin Gang, M.D. (Changhai Hospital) · Sites: Shanghai, Shanghai Municipality; Jiaxing, Zhejiang +1 more · Age: 1899 yrs
Intent of Surgery for IPMN
Actively Recruiting
PI: Greg Sacks, MD MPH PhD (NYU Langone Health) · Sites: Phoenix, Arizona; Baltimore, Maryland +12 more · Age: 1899 yrs
Identification of New Theranostic Biomarkers of Pancreatic Tumor Progression
Actively Recruiting
PI: Carmine Carbone, PhD (Fondazione Policlinico Universitario Agostino Geme) · Sites: Roma; Rome · Age: 1899 yrs
Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions
Actively Recruiting
PI: Somashekar Krishna, MD, MPH (Ohio State University) · Sites: Scottsdale, Arizona; Stanford, California +8 more · Age: 1899 yrs

Specialists

Showing 25 of 30View all specialists →
MF
Mokenge P Malafa, MD, FACS
TAMPA, FL
Specialist
PI on 1 active trial
JP
Jennifer Permuth, PhD
Specialist
PI on 2 active trials
WM
Wang Bei Lei, M.D.
Specialist
PI on 1 active trial
AF
Adrian Fox
Specialist
PI on 1 active trial17 Intraductal papillary mucinous carcinoma of pancreas publications
JM
Jeong Min Lee, MD
Specialist
PI on 6 active trials
WM
Wendy K Chung, MD
Specialist
PI on 3 active trials1 Intraductal papillary mucinous carcinoma of pancreas publication
HM
Harish Lavu, MD
PHILADELPHIA, PA
Specialist
PI on 3 active trials
EM
Elizabeth Hecht, MD
BROOKLYN, NY
Specialist
PI on 2 active trials
RA
Ross A Abrams
CHICAGO, IL
Specialist
PI on 1 active trial6 Intraductal papillary mucinous carcinoma of pancreas publications
KM
Kimberly S Kirkwood, MD
ITHACA, NY
Specialist
PI on 1 active trial
PM
Paige M Bracci, PhD, MPH, MS
Specialist
PI on 1 active trial
GP
Gregory Springett, M.D., Ph.D.
TAMPA, FL
Specialist
PI on 2 active trials
GH
Gregory Haber
NEW YORK, NY
Specialist
PI on 1 active trial
DB
David C Binion
PITTSBURGH, PA
Specialist
PI on 1 active trial
HN
Heini Nieminen
Specialist
PI on 1 active trial
MC
Marco Del Chiaro
Specialist
PI on 1 active trial
JC
Jean Baptiste JC CHEVAUX
Specialist
PI on 1 active trial
XW
Xi Wu
Specialist
PI on 1 active trial
JG
Jin Gang
Specialist
PI on 1 active trial
SS
Susanne Stanzel
Specialist
PI on 1 active trial
CS
Christian M Schmidt
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Intraductal papillary mucinous carcinoma of pancreas.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Intraductal papillary mucinous carcinoma of pancreasForum →

No community posts yet. Be the first to share your experience with Intraductal papillary mucinous carcinoma of pancreas.

Start the conversation →

Latest news about Intraductal papillary mucinous carcinoma of pancreas

Disease timeline:

New recruiting trial: Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas

A new clinical trial is recruiting patients for Intraductal papillary mucinous carcinoma of pancreas

New recruiting trial: ExoLuminate Study for Early Detection of Pancreatic Cancer

A new clinical trial is recruiting patients for Intraductal papillary mucinous carcinoma of pancreas

New recruiting trial: Identification of New Theranostic Biomarkers of Pancreatic Tumor Progression

A new clinical trial is recruiting patients for Intraductal papillary mucinous carcinoma of pancreas

New recruiting trial: Confocal Laser Endomicroscopy as an Imaging Biomarker for the Diagnosis of Pancreatic Cystic Lesions

A new clinical trial is recruiting patients for Intraductal papillary mucinous carcinoma of pancreas

New recruiting trial: Intent of Surgery for IPMN

A new clinical trial is recruiting patients for Intraductal papillary mucinous carcinoma of pancreas

New recruiting trial: Integration of Multiomics Markers for Invasive IPMNs Identification Through the Set-up of the INvasive Cyst bIomarkers Detection (INCITE) Consortium

A new clinical trial is recruiting patients for Intraductal papillary mucinous carcinoma of pancreas

New recruiting trial: AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort

A new clinical trial is recruiting patients for Intraductal papillary mucinous carcinoma of pancreas

New recruiting trial: Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas

A new clinical trial is recruiting patients for Intraductal papillary mucinous carcinoma of pancreas

New recruiting trial: Endocrine, Metabolic, Inflammatory Biomarkers to Identify Highgrade Dysplasia/invasive Carcinoma in Patients with IPMN of the Pancreas

A new clinical trial is recruiting patients for Intraductal papillary mucinous carcinoma of pancreas

New recruiting trial: Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer

A new clinical trial is recruiting patients for Intraductal papillary mucinous carcinoma of pancreas

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Has the cancer spread beyond the pancreas, and am I a candidate for surgery?,Which type of surgery would I need, and what are the risks and recovery time?,Should I have genetic testing to see if a hereditary cancer syndrome runs in my family?,What chemotherapy or other treatments would you recommend after surgery, and what side effects should I expect?,How will my digestion and blood sugar be affected, and what support will I get to manage those changes?,How often will I need follow-up scans, and what are we watching for?,Are there any clinical trials I might be eligible for?

Common questions about Intraductal papillary mucinous carcinoma of pancreas

What is Intraductal papillary mucinous carcinoma of pancreas?

Intraductal papillary mucinous carcinoma of the pancreas, often called IPMC or malignant IPMN (intraductal papillary mucinous neoplasm), is a type of pancreatic cancer that starts inside the ducts of the pancreas — the tubes that carry digestive juices. It begins as a slow-growing, mucus-producing growth called an IPMN, which over time can turn into cancer. The pancreas sits behind the stomach and plays two important roles: helping digest food and controlling blood sugar. When cancer develops in its ducts, it can block the flow of digestive enzymes and affect how the whole organ works. People

How is Intraductal papillary mucinous carcinoma of pancreas inherited?

Intraductal papillary mucinous carcinoma of pancreas follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Intraductal papillary mucinous carcinoma of pancreas typically begin?

Typical onset of Intraductal papillary mucinous carcinoma of pancreas is adult. Age of onset can vary across affected individuals.

Are there clinical trials for Intraductal papillary mucinous carcinoma of pancreas?

Yes — 16 recruiting clinical trials are currently listed for Intraductal papillary mucinous carcinoma of pancreas on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Intraductal papillary mucinous carcinoma of pancreas?

25 specialists and care centers treating Intraductal papillary mucinous carcinoma of pancreas are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.